Abstract / Summary
At a time when addiction field professionals and advocates await a decision on the possible rescheduling of marijuana, a report from Congress's Government Accountability Office (GAO) has uncovered gaps in the overall evaluations conducted by the federal agencies involved in all drug scheduling decision‐making processes.
Topics
Opioid Use Disorder Treatmentdrug schedulingControlled Substances ActDrug Enforcement AdministrationFood and Drug Administrationfederal drug policyevaluation proceduressubstance abuse policyOpen access